Fractionated radioimmunotherapy with I-131 chimeric antibody G250 (cG250) in metastatic renal cancer

被引：0
|
作者：
Divgi, CR
O'Donoghue, JA
McGagh, D
Anwar, K
Motzer, R
Welt, S
Larson, SM
Old, LJ
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Ludwig Inst Canc Res, New York, NY USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1999年 / 26卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
PS423
引用
收藏
页码：1158 / 1158
页数：1
相关论文
共 50 条
  • [1] Fractionated radioimmunotherapy with I-131-labeled chimeric antibody G250 (cG250) in patients with metastatic renal cell carcinoma.
    Divgi, CR
    O'Donoghue, JA
    McGagh, DA
    Motzer, RJ
    Anwar, K
    Sheikh, A
    Gonzalez, RS
    Welt, S
    Old, LJ
    Larson, SM
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 217P - 217P
  • [2] RADIOIMMUNOTHERAPY (RIT) WITH I-131 MONOCLONAL-ANTIBODY (MAB) G250 IN METASTATIC RENAL-CANCER
    DIVGI, CR
    BANDER, NH
    GRAHAM, MC
    SCOTT, AM
    WELT, S
    MOTZER, RJ
    OOSTERWIJK, E
    LARSON, SM
    OLD, LJ
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (05) : P101 - P101
  • [3] Phase I/II radioimmunotherapy with I-131 labeled chimeric monoclonal antibody cG250 in patients with metastasized renal cell carcinoma.
    Steffens, MG
    Boerman, OC
    Oosterwijk, E
    Oyen, WJG
    De Mulder, PHM
    Witjes, JA
    Oosterhof, GON
    Debruyne, FMJ
    Corstens, FHM
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 247P - 247P
  • [4] Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250
    Steffens, MG
    Boerman, OC
    de Mulder, PHM
    Oyen, WJG
    Buijs, WCAM
    Witjes, JA
    van den Broek, WJM
    Oosterwijk-Wakka, JC
    Debruyne, FMJ
    Corstens, FHM
    Oosterwijk, E
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3268S - 3274S
  • [5] Phase I clinical trial with fractionated radioimmunotherapy using 13I-labeled chimeric G250 in metastatic renal cancer
    Divgi, CR
    O'Donoghue, JA
    Welt, S
    O'Neel, J
    Finn, R
    Motzer, RJ
    Jungbluth, A
    Hoffman, E
    Ritter, G
    Larson, SM
    Old, LJ
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (08) : 1412 - 1421
  • [6] Red marrow dosimetry after administration of I-131 labeled chimeric G250 monoclonal antibody (cG250) in patients with renal cell carcinoma, based on planar gamma camera images.
    Buijs, WCAM
    Steffens, MG
    Boerman, O
    Siegel, JA
    Oosterwijk, E
    Corstens, FHM
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 958 - 958
  • [7] Higher uptake in renal cell carcinoma (RCC) metastases with 111In-labeled chimeric monoclonal antibody G250 (cG250) than with 131I-cG250 in an intra-patient comparison.
    Brouwers, AH
    Buijs, WC
    Boerman, OC
    Oosterwijk, E
    De Mulder, PH
    Corstens, FH
    Mulders, PF
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 171P - 172P
  • [8] Radioimmunotargeting with I-131 labeled chimeric G250 monoclonal antibody in patients with renal cell carcinoma.
    Steffens, MG
    Boerman, OC
    Oosterwijk, E
    Oosterhof, GON
    Witjes, JA
    OosterwijkWakka, JC
    Koenders, E
    Debruyne, FMJ
    Corstens, FHM
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (05) : 740 - 740
  • [9] Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250
    Hendrickx, Baudewijn W.
    Punt, Cees J. A.
    Boerman, Otto C.
    Postema, Ernst J.
    Oosterwijk, Egbert
    Mavridu, Agapi
    Corstens, Frans H. M.
    Oyen, Wim J. G.
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (03) : 263 - 268
  • [10] Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody cG250
    Hendrickx, B. W.
    Punt, C. J. A.
    Boerman, O. C.
    Postema, E. J.
    Mavridu, A.
    Corstens, F. C.
    Oyen, W. J. G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S206 - S206
12345